NCT05182164 - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Soft Tissue Sarcoma AdultAdvanced Soft-tissue SarcomaEwing SarcomaOsteosarcomaUndifferentiated Pleomorphic Sarcoma

Interventions

DRUG

Association of pembrolizumab + cabozantinib

"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."

Trial Locations (10)

13009

RECRUITING

Institut Paoli Calmettes, Marseille

13385

RECRUITING

Hôpital La Timone, Marseille

21079

RECRUITING

Centre Georges François Leclerc, Dijon

31059

NOT_YET_RECRUITING

IUCT Oncopole, Toulouse

33076

RECRUITING

Institut Bergonie, Bordeaux

44805

RECRUITING

Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain

59020

NOT_YET_RECRUITING

Centre Oscar Lambret, Lille

69008

NOT_YET_RECRUITING

Centre Leon Berard, Lyon

75248

NOT_YET_RECRUITING

Institut Curie, Paris

94805

RECRUITING

Institut Gustave Roussy, Villejuif